MCID: ADR041
MIFTS: 49

Adrenal Cortical Adenoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adrenal Cortical Adenoma

MalaCards integrated aliases for Adrenal Cortical Adenoma:

Name: Adrenal Cortical Adenoma 11 14 71
Adrenocortical Adenoma 11 5 16 75
Adenoma Adrenocortical 53

Classifications:



External Ids:

Disease Ontology 11 DOID:0050891
UMLS 71 C0206667

Summaries for Adrenal Cortical Adenoma

Disease Ontology: 11 An adrenal adenoma that is a benign tumor of the adrenal cortex.

MalaCards based summary: Adrenal Cortical Adenoma, also known as adrenocortical adenoma, is related to adrenal adenoma and adenoma. An important gene associated with Adrenal Cortical Adenoma is MEN1 (Menin 1), and among its related pathways/superpathways are Metapathway biotransformation Phase I and II and Diseases of glycosylation. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include adrenal cortex, cortex and pituitary, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Wikipedia: 75 Adrenocortical adenoma is commonly described as a benign neoplasm emerging from the cells that comprise... more...

Related Diseases for Adrenal Cortical Adenoma

Diseases related to Adrenal Cortical Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 adrenal adenoma 31.1 REN PRKAR1A POMC MIR483 MEN1 MC2R
2 adenoma 31.0 SYP REN PRKAR1A POMC MEN1 MC2R
3 premature ovarian failure 7 30.7 POMC NR5A1
4 acne 30.5 POMC CYP21A2 CYP17A1
5 pheochromocytoma 30.5 SYP REN POMC MEN1 IGF2 CHGA
6 adrenogenital syndrome 30.4 SYP INHA CYP21A2
7 neurilemmoma 30.4 SYP PRKAR1A MLANA
8 hypokalemia 30.3 REN POMC CYP17A1 CYP11B1
9 pituitary-dependent cushing's disease 30.3 POMC MC2R
10 amenorrhea 30.3 POMC NR5A1 CYP17A1
11 hemangioma 30.3 SYP MEN1 IGF2 CHGA
12 liddle syndrome 1 30.3 REN POMC CYP11B1
13 multiple endocrine neoplasia 30.2 SYP PRKAR1A POMC MEN1 CHGA
14 hyperandrogenism 30.2 POMC IGF2 CYP21A2 CYP17A1 CYP11A1
15 functioning pituitary adenoma 30.2 PRKAR1A POMC MEN1
16 beckwith-wiedemann syndrome 30.2 PRKAR1A MIR483 MEN1 IGF2
17 primary hyperparathyroidism 30.2 PRKAR1A MEN1 CHGA
18 acth-independent macronodular adrenal hyperplasia 30.2 PRKAR1A POMC MEN1 MC2R GIPR CYP11B1
19 hyperparathyroidism 30.2 PRKAR1A MEN1 CHGA
20 carcinoid syndrome 30.2 SYP CHGA
21 parathyroid adenoma 30.2 SYP PRKAR1A MEN1 CHGA
22 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 30.2 NR5A1 MC2R CYP11A1
23 appendix adenocarcinoma 30.2 SYP CHGA
24 carcinoid tumors, intestinal 30.2 SYP MEN1 CHGA
25 acute adrenal insufficiency 30.1 POMC CYP21A2 CYP11A1
26 granular cell tumor 30.1 SYP MLANA INHA
27 prolactinoma 30.1 PRKAR1A POMC MEN1 CHGA
28 meningioma, familial 30.1 SYP PRKAR1A POMC MLANA MEN1 IGF2
29 polycystic ovary syndrome 30.0 SULT2A1 POMC IGF2 CYP21A2 CYP17A1 CYP11A1
30 pituitary adenoma 29.9 PRKAR1A POMC MEN1 CHGA
31 multiple endocrine neoplasia, type i 29.9 SYP PRKAR1A POMC MIR483 MEN1 CHGA
32 primary pigmented nodular adrenocortical disease 29.9 PRKAR1A POMC MIR483 MEN1 MC2R CYP17A1
33 hypogonadotropic hypogonadism 29.8 POMC NR5A1 INHA CYP21A2 CYP17A1
34 acromegaly 29.8 POMC MEN1 IGF2
35 hypertension, essential 29.7 REN POMC MIR483 MEN1 CYP17A1 CYP11B1
36 pseudohermaphroditism 29.7 POMC NR5A1 CYP21A2 CYP17A1 CYP11B1 CYP11A1
37 leydig cell tumor 29.7 SYP NR5A1 INHA CYP21A2 CYP17A1 CYP11A1
38 gastrointestinal stromal tumor 29.7 SYP MLANA MEN1 IGF2 CHGA
39 paraganglioma 29.7 SYP REN POMC MLANA MEN1 IGF2
40 conn's syndrome 29.5 SYP SULT2A1 REN PRKAR1A POMC NR5A1
41 wilms tumor 1 29.4 SYP REN NR5A1 MLANA MIR483 IGF2
42 familial glucocorticoid deficiency 29.3 REN POMC NR5A1 MC2R CYP21A2 CYP17A1
43 type 2 diabetes mellitus 29.1 REN POMC MIR483 IGF2 GIPR CYP21A2
44 carney complex variant 29.1 PRKAR1A POMC NR5A1 MLANA MIR483 MEN1
45 lipoid congenital adrenal hyperplasia 28.9 SULT2A1 REN POMC NR5A1 MC2R CYP21A2
46 adrenal carcinoma 28.5 SYP REN PRKAR1A POMC NR5A1 MLANA
47 adrenal cortical carcinoma 28.0 SYP SULT2A1 REN PRKAR1A POMC NR5A1
48 adrenal gland disease 27.9 SYP REN PRKAR1A POMC NR5A1 MLANA
49 acth-independent cushing syndrome 11.2
50 breast ductal adenoma 10.4 PRKAR1A GIPR

Graphical network of the top 20 diseases related to Adrenal Cortical Adenoma:



Diseases related to Adrenal Cortical Adenoma

Symptoms & Phenotypes for Adrenal Cortical Adenoma

GenomeRNAi Phenotypes related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CHGA CYP11B1 CYP21A2 GIPR IGF2 MC2R

MGI Mouse Phenotypes related to Adrenal Cortical Adenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 CHGA CYB5A CYP11A1 CYP11B1 CYP17A1 GIPR
2 nervous system MP:0003631 10.22 CHGA CYP11A1 CYP11B1 IGF2 MC2R MEN1
3 growth/size/body region MP:0005378 10.21 CHGA CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2
4 muscle MP:0005369 10.06 CHGA CYP11A1 CYP11B1 IGF2 MEN1 NR2F1
5 endocrine/exocrine gland MP:0005379 10.06 CHGA CYP11A1 CYP11B1 GIPR IGF2 INHA
6 liver/biliary system MP:0005370 10.03 CYB5A CYP11A1 CYP11B1 IGF2 INHA MEN1
7 cardiovascular system MP:0005385 10.03 CHGA CYP11A1 CYP11B1 CYP17A1 IGF2 INHA
8 behavior/neurological MP:0005386 9.97 CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2 MC2R
9 reproductive system MP:0005389 9.65 CHGA CYP11A1 CYP11B1 CYP17A1 IGF2 INHA
10 mortality/aging MP:0010768 9.47 CHGA CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2

Drugs & Therapeutics for Adrenal Cortical Adenoma

Drugs for Adrenal Cortical Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
3
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Nutmeg Approved Phase 4
8 Hydrocortisone 17-butyrate 21-propionate Phase 4
9 Epinephryl borate Phase 4
10 Mace Phase 4
11 Melanocyte-Stimulating Hormones Phase 3
12 Adrenocorticotropic Hormone Phase 3
13
beta-Endorphin Phase 3
14
Dopamine Approved 62-31-7, 51-61-6 681
15
Ethanol Approved 64-17-5 702
16
Zinc cation Approved, Experimental, Investigational 7440-66-6, 23713-49-7 32051
17
Amlodipine Approved 88150-42-9 2162
18
Diltiazem Approved, Investigational 42399-41-7 39186
19
Prazosin Approved 19216-56-9 4893
20
Angiotensin II Approved, Investigational 68521-88-0, 11128-99-7, 4474-91-3 172198
21
Spironolactone Approved 1952-01-7, 52-01-7 5833
22
Bisoprolol Approved 66722-44-9 2405
23
Indapamide Approved 26807-65-8 3702
24
Prasterone Approved, Investigational, Nutraceutical 53-43-0 5881
25 Insulin, Globin Zinc
26
Insulin
27 Hypoglycemic Agents
28 DHEA (Dehydroepiandrosterone)
29 Antineoplastic Agents, Hormonal
30 Antiemetics
31 glucocorticoids
32 Anti-Inflammatory Agents
33 Gastrointestinal Agents
34 Bronchodilator Agents
35 Neurotransmitter Agents
36 Adrenergic beta-Agonists
37 Adrenergic alpha-Agonists
38 Anti-Asthmatic Agents
39 Adrenergic Agonists
40 Adrenergic Agents
41 Vasoconstrictor Agents
42 Respiratory System Agents
43 Mydriatics
44 Sympathomimetics
45 Antihypertensive Agents
46
Angiotensinogen 16133225
47 Angiotensin-Converting Enzyme Inhibitors
48 Angiotensin Receptor Antagonists
49 Giapreza
50 Hormones

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women Recruiting NCT05038878 Phase 4 Elagolix
2 Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant Recruiting NCT04308590 Phase 3 relacorilant
3 A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212 Completed NCT02150213 Phase 2 BGG492
4 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
5 Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial Unknown status NCT02030587
6 Natural History of Benign Nonfunctioning Adrenal Tumors: 10 Year Follow-up Results Unknown status NCT04616703
7 Expression of D2-Like Dopamine Receptor of Human Aldosterone-Producing Adenoma and Its Role in Regulation of Aldosterone Secretion and Cell Proliferation Unknown status NCT00173446
8 Feasibility Study of RadioFrequency Endoscopic ABlation, With ULtrasound Guidance, as a Non-surgical, Adrenal Sparing Treatment for Aldosterone-producing Adenomas Unknown status NCT03405025
9 Evaluation of the Diagnostic Utility of Serum Dexamethasone Measurements in the Overnight 1mg Dexamethasone Suppression Test in Patients Investigated for Cushing's Syndrome and Incidentalomas Unknown status NCT01504555
10 Complex Cystic Benign Adrenal Incidentalomas Mimicking Non-adenomatous Masses; Rare Pathologies: Clinical Features and Outcomes. Case Series With Short Review of Literature. Completed NCT03739918
11 Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism: Evaluation of the Blood Pressure Control and of Its Safety. Completed NCT02756754
12 Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue Completed NCT01949714
13 Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis Completed NCT04761354
14 Morbidity and Mortality in Patients With Adrenal Incidentalomas With and Without Autonomous Cortisol Secretion Completed NCT03919734
15 Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions on Cross-sectional Imaging (CT or MRI) Completed NCT04071561
16 Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma: Myth or Reality? Completed NCT00768365
17 Is There Anything New in the Field of Large Adrenal Tumors ? Completed NCT03830593
18 The Prevalence and Characteristics of Adrenal Incidentaloma: A Prospective Study Completed NCT04682938
19 Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) Recruiting NCT04328181
20 Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations (ITACA Study) Recruiting NCT04127552
21 The Cross-sectional Study and Longitudinal Study of the Diagnostic Efficiency of Serum Dehydroepiandrosterone Sulfate in Subclinical Hypercortisolism Recruiting NCT04833192
22 If Adrenal Incidentalomas Have the Influences to Occur and Progress in Patients With Stroke Recruiting NCT05237817
23 Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield Recruiting NCT02324647
24 China Adrenal Disease Registry Study Recruiting NCT04890444
25 Long-term Effects of Adrenalectomy on Metabolic Syndrome, Glucose Metabolism, Lipid Metabolism, and Bone Metabolism in Subclinical Cushing's Syndrome of Adrenal Incidentaloma Recruiting NCT01382420
26 A Single Center, Prospective, Observational Study to Explore and Evaluate the Differences of Cognitive Function and Brain Function Between Non-functioning Adrenal Adenomas and Autonomous Cortisol Secretion Patients, and the Different Treatments Methods on Cognitive Function and Brain Function in Patients With Autonomous Cortisol Secretion Recruiting NCT05357456
27 Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas Active, not recruiting NCT02364089 Standardized medical treatment of hypertension by SAHR
28 Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas on Cardiovascular, Metabolic, Neuropsychological and Bone Manifestations: Respective Roles of Cortisol Secretion and Glucocorticoid Sensitivity Active, not recruiting NCT04860180
29 Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry Active, not recruiting NCT04917757
30 A Prospective Cohort Study for Patients With Adrenal Diseases Enrolling by invitation NCT03474237

Search NIH Clinical Center for Adrenal Cortical Adenoma

Genetic Tests for Adrenal Cortical Adenoma

Anatomical Context for Adrenal Cortical Adenoma

Organs/tissues related to Adrenal Cortical Adenoma:

MalaCards : Adrenal Cortex, Cortex, Pituitary, Adrenal Gland, Bone, Brain, Thyroid

Publications for Adrenal Cortical Adenoma

Articles related to Adrenal Cortical Adenoma:

(show top 50) (show all 1068)
# Title Authors PMID Year
1
MEN I gene mutations in sporadic adrenal adenomas. 5
10647896 1999
2
Biallelic APC inactivation was responsible for functional adrenocortical adenoma in familial adenomatous polyposis with novel germline mutation of the APC gene: report of a case. 53 62
19684041 2009
3
Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). 53 62
18419788 2008
4
The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses. 53 62
18393131 2008
5
Unique association of non-functioning pheochromocytoma, ganglioneuroma, adrenal cortical adenoma, hepatic and vertebral hemangiomas in a patient with a new intronic variant in the VHL gene. 53 62
16483185 2005
6
Significance of inhibin in reproductive pathophysiology and current clinical applications. 53 62
15970011 2005
7
Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. 53 62
15287021 2004
8
Myxoid adrenocortical adenoma with a pseudoglandular pattern. 53 62
15235911 2004
9
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. 53 62
15168774 2004
10
[The expression of A103 and inhibin alpha in adrenocortical adenoma by high-throughput tissue microarray techniques]. 53 62
12910679 2003
11
Massive adrenocortical adenoma following long-term treatment of 21-hydroxylase deficiency. 53 62
11832743 2002
12
Immunoexpression of inhibin alpha-subunit in adrenal neoplasms. 53 62
11556749 2001
13
Expression of adrenocorticotropin receptor gene in adrenocortical adenomas from patients with Cushing syndrome: possible contribution for the autonomous production of cortisol. 53 62
11420487 2001
14
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. 53 62
11158012 2001
15
Virilizing adrenocortical adenoma: in vitro steroidogenesis, immunohistochemical studies of steroidogenic enzymes, and gene expression of corticotropin receptor. 53 62
10216530 1999
16
Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. 53 62
9761377 1998
17
[Aberrant expression of the GIP (Gastric Inhibitory Polypeptide) receptor in an adrenal cortical adenoma responsible for a case of food-dependent Cushing's syndrome]. 53 62
10333644 1998
18
Aldosterone-producing adrenocortical adenoma complicated by chronic renal failure. Case report and review of the literature. 53 62
9845833 1998
19
Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. 53 62
9249232 1997
20
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies. 53 62
8977764 1996
21
Immunolocalization of dehydroepiandrosterone sulfotransferase in normal and pathologic human adrenal gland. 53 62
8751327 1995
22
Expression of a high molecular weight form of insulin-like growth factor II in a Beckwith-Wiedemann syndrome associated adrenocortical adenoma. 53 62
7621447 1995
23
In-vitro evidence for the regulation of 17,20-lyase activity by cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome. 53 62
8137519 1994
24
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas. 53 62
8288710 1994
25
Disordered expression of adrenal steroidogenic P450 mRNAs in incidentally discovered nonfunctioning adrenal adenoma. 53 62
1535042 1992
26
Decreased levels of steroid 21-hydroxylase [P450(c21)] and its mRNA in an adrenocortical adenoma associated with 21-hydroxylase deficiency. 53 62
2101789 1990
27
Endocrine activity of the "silent" adrenocortical adenoma is uncovered by response to corticotropin-releasing hormone. 53 62
2165544 1990
28
68Ga-DOTATATE PET/CT of ACTH-Independent Cushing Syndrome Due to Ectopic Adrenocortical Adenoma. 62
36469068 2023
29
Adrenocortical adenoma arising from adreno-hepatic fusion: A pitfall for an overdiagnosis. 62
36468827 2022
30
Left adrenal aldosteronism coexisting with left paraaortic paraganglioma presenting as bilateral adrenal and left paraaortic tumors- comprehensive adrenal evaluation aiding perfect management: a case report. 62
36371163 2022
31
Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy. 62
36447826 2022
32
Approach to Fine Needle Aspiration of Adrenal Gland Lesions. 62
35878423 2022
33
Altered expression of the IGF2‑H19 locus and mitochondrial respiratory complexes in adrenocortical carcinoma. 62
36169175 2022
34
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET. 62
35241482 2022
35
Mixed ganglioneuroma and cortical adenoma in adrenal gland: A case report. 62
36451378 2022
36
Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. 62
36095315 2022
37
Diagnostic and prognostic utility of SF-1 in adrenal cortical tumours. 62
36308186 2022
38
A 15-cm Adrenal Incidentaloma Suggested on Upper Endoscopy and Resected Laparoscopically. 62
36381726 2022
39
Adrenal myelolipoma: Defining the role of surgery. A case report. 62
36030765 2022
40
Exploratory Circular RNA Profiling in Adrenocortical Tumors. 62
36077848 2022
41
Retroperitoneal Bronchogenic Cyst Adjacent to Adrenocortical Adenoma. 62
35185056 2022
42
ACTH-independent production of 11-oxygenated androgens and glucocorticoids in an adrenocortical adenoma. 62
36165744 2022
43
Genetic Dissection of Primary Aldosteronism in a Patient with MEN1 and Ipsilateral Adrenocortical Carcinoma and Adenoma. 62
36179244 2022
44
ACTH-Independent Cushing's Syndrome Caused by an Ectopic Adrenocortical Adenoma in the Renal Hilum. 62
36010286 2022
45
Association of DNA methylation with steroidogenic enzymes in Cushing's adenoma. 62
35675123 2022
46
Myelolipoma/extramedullary hematopoiesis within adrenal cortical adenoma increased in size during chronic myelogenous leukemia treatment. 62
35088173 2022
47
Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma. 62
35467062 2022
48
Adrenal gland cytology reporting: a multi-institutional proposal for a standardized reporting system. 62
35244974 2022
49
Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. 62
35091676 2022
50
CT-based Abdominal Adipose Tissue Area Changes in Patients Undergoing Adrenalectomy Due to Cushing's Syndrome and Non-functioning Adenomas. 62
34359077 2022

Variations for Adrenal Cortical Adenoma

ClinVar genetic disease variations for Adrenal Cortical Adenoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MEN1 NM_001370259.2(MEN1):c.1654A>T (p.Thr552Ser) SNV Pathogenic
16698 rs121913035 GRCh37: 11:64571985-64571985
GRCh38: 11:64804513-64804513

Cosmic variations for Adrenal Cortical Adenoma:

8 (show top 50) (show all 118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM86624499 RB1 pituitary,NS,adenoma,ACTH-FSH-GH-LH-PRL c.1861C>A p.R621S 13:48456250-48456250 7
2 COSM150337228 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
3 COSM151605250 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
4 COSM150962042 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
5 COSM151491351 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
6 COSM105887915 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
7 COSM110179104 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
8 COSM150547790 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
9 COSM150961028 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
10 COSM111910236 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
11 COSM102452270 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
12 COSM150526110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
13 COSM151827775 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
14 COSM150088294 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
15 COSM102412283 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
16 COSM110181025 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
17 COSM150300123 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
18 COSM146902958 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
19 COSM150454007 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
20 COSM151356165 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 7
21 COSM150480970 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
22 COSM150141897 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
23 COSM151979920 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
24 COSM151836221 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
25 COSM111893529 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
26 COSM150660304 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
27 COSM146245709 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
28 COSM111894601 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
29 COSM150867955 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
30 COSM151353823 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 7
31 COSM111038093 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
32 COSM102485110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
33 COSM151345590 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
34 COSM150868805 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
35 COSM151592258 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
36 COSM150274829 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
37 COSM102450402 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
38 COSM102380394 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
39 COSM150827985 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
40 COSM151559313 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 7
41 COSM110212608 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
42 COSM150452305 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
43 COSM151343442 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 7
44 COSM151344333 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
45 COSM151570765 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 7
46 COSM149991639 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 7
47 COSM146867471 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7
48 COSM149959645 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 7
49 COSM111917881 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 7
50 COSM151826992 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 7

Expression for Adrenal Cortical Adenoma

Search GEO for disease gene expression data for Adrenal Cortical Adenoma.

Pathways for Adrenal Cortical Adenoma

Pathways related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 SULT2A1 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1
2
Show member pathways
12.49 CYP11A1 CYP11B1 CYP17A1 CYP21A2 MC2R POMC
3
Show member pathways
12.44 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1 CYB5A
4
Show member pathways
12.36 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1
5
Show member pathways
11.94 PRKAR1A POMC MC2R GIPR
6
Show member pathways
11.39 SULT2A1 CYP17A1 CYP11B1
7
Show member pathways
11.34 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1
8 10.99 CYP21A2 CYP17A1 CYP11B1 CYP11A1
9 10.98 SULT2A1 POMC CYP21A2 CYP11B1 CYP11A1
10 10.47 CYP17A1 CYP11A1 CYB5A

GO Terms for Adrenal Cortical Adenoma

Biological processes related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.92 REN POMC CYP11B1 CHGA
2 sterol metabolic process GO:0016125 9.85 CYP21A2 CYP11B1 CYP11A1
3 C21-steroid hormone biosynthetic process GO:0006700 9.73 CYP11B1 CYP11A1
4 cellular response to peptide hormone stimulus GO:0071375 9.73 CYP11A1 CYP11B1 MEN1
5 cortisol metabolic process GO:0034650 9.71 CYP11B1 CYP11A1
6 steroid biosynthetic process GO:0006694 9.63 CYP21A2 CYP17A1 CYP11B1 CYP11A1
7 steroid metabolic process GO:0008202 9.56 SULT2A1 CYP21A2 CYP17A1 CYP11B1 CYP11A1
8 glucocorticoid biosynthetic process GO:0006704 9.23 CYP21A2 CYP17A1 CYP11B1 CYP11A1

Molecular functions related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.86 CYP21A2 CYP17A1 CYP11B1 CYP11A1
2 heme binding GO:0020037 9.65 CYP21A2 CYP17A1 CYP11B1 CYP11A1 CYB5A
3 monooxygenase activity GO:0004497 9.46 CYP21A2 CYP17A1 CYP11B1 CYP11A1
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP21A2 CYP17A1 CYP11B1 CYP11A1

Sources for Adrenal Cortical Adenoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....